Narrative role of vitamin D receptor with osteoporosis and obesity in a sample of Egyptian females: a pilot study

Nayera E. Hassan¹, Sahar A. El-Masry¹*, Waheba Ahmed Zarouk², Ghada Nour Eldeen², Rehab M. Mosaad², Mahmoud A. S. Afify¹, Manal M. Aly¹ and Aya Khalil¹

Abstract

Background: Vitamin D receptor (VDR) is known as one of the cellular regulators for several metabolic pathways indicating its pivotal role in the pathological pathway of numerous diseases. Considering the high frequency of osteoporosis and obesity among women, the current study aimed to explore the prospective assembly of the most frequent two VDR loci, single nucleotide polymorphism SNPs rs731236 (TaqI) and rs7975232 (ApaI) with a genetic predisposition to osteoporosis (skeletal) and obesity (chronic non-skeletal disorders), in Egyptian women. This was a cross-sectional study, including 97 Egyptian females (25–65 years), randomly chosen, from all employees and workers of the National Research Centre, Egypt. Anthropometric measurements (weight, height, BMI), dual-energy X-ray absorptiometry (DEXA), and molecular genetic analysis were done.

Results: The variation of ApaI genotype between the normal and osteoporotic groups denotes a remarkable association of the homozygote ApaI genotype with osteoporosis risk. Among the normal weight group, bone mineral density (BMD) was significantly associated with TaqI VDR gene polymorphism as the presence of the heterozygote genotype was accompanied with higher BMD while the homozygote one was detected with lower BMD. Also, TaqI VDR gene polymorphism was significantly associated with BMI when participants were divided according to the presence of osteoporosis; increased BMI was expressed in the non-osteoporotic women group carrying the homozygote genotype of Taq I VDR gene while the presence of the heterozygote genotype (TaqI) in the osteoporotic group was associated with increased BMI.

Conclusions: The heterozygote TaqI genotype is protective against the osteoporosis phenotype and accompanied with increased BMI among osteoporotic women, while the homozygote Apal genotype has a significant association with osteoporosis risk.

Keywords: Vitamin D receptor polymorphism, TaqI genotype, Apal genotype, Osteoporosis, Obesity, Egyptian females

Background

Osteoporosis and obesity are worldwide health problems and greatly affecting public health, being often associated with high morbidity and mortality leading to reduced quality of life and increased economic cost [1]. Worldwide, there is a difference in gender as one-third of women above the age of 50 years were exposed to osteoporotic fractures in relation to one-fifth of men of the same age group [2]. The prevalence of obesity worldwide indicates a pandemic; the health and demographic survey enrolled by the Health Ministry in Egypt indicates that around 46.3% of females are obese [3]. The etiology of both diseases has been supposed to arise from dysregulation of bone marrow mesenchymal stromal cells

* Correspondence: masrysa@yahoo.com
¹Biological Anthropology Department, Medical Research Division, National Research Centre, 33 El-Bohooth St., Dokki, Cairo, Giza 12622, Egypt
Full list of author information is available at the end of the article
which are considered as a common precursor cell for both osteoblasts and adipocytes [4].

Data originating from twin studies has reported that genetic factors represent up to 85% of diversity in bone mass [5] and the coincidence for fat mass among monozygotic (MZ) twins has been denoted to range from 70 to 90%, while in dizygotic (DZ) twins it is 35–45% [6].

Vitamin D metabolic functions occur through the binding of the active form of vitamin D receptor (VDR), 1, 25-dihydroxy-vitamin D (1, 25(OH)2D), to it. Then, the retinoic acid receptor (RXR) joins this complex, producing ultimately heterodimers that act on vitamin D response elements targeting gene promoter regions. A cascade of transcriptional regulations affecting target genes occurs. VDRs exist nearly in all human tissues including adipose tissue. They are mediating the function of vitamin D and so are essential for epigenome and expression of more than 1000 genes [7].

The human VDR gene is localized on chromosome 12q13.1 which spans ~ 75 kb genomic DNA and is presented with 11 exons [8]. Several VDR genetic polymorphisms are reported. The 3′ end region is part of the ligand-binding domain of the VDR. The reported polymorphisms such as that of Apal and TaqI, which are located at the 3′ untranslated region (3′UTR) of the VDR gene, are the most prevalent and extensively studied genetic markers in relation to bone mineral density (BMD) variations in adult females as it influences the mRNA stability and VDR expression [9]. The structural protein variations secondary to Apal and TaqI polymorphisms may lead to alternation of the binding specificity of vitamin D. Mutations in functional regions of the VDR gene affect the metabolism of minerals—especially calcium—and therefore bone density [10]. Variations in VDR genetic alleles have been demonstrated to be associated with metabolic syndrome (MS) and its components including anthropometric parameters related to obesity. Although the genetic background of obesity is complex, recently, it was evidenced that functional polymorphisms of certain genes might affect the whole interindividual susceptibility to obesity [11,12].

On contrary, some studies have reported that there is no association between VDR gene polymorphisms and the risk for MS development [13–15]. This debate remains unclear and requires further large-scale studies.

evidence that; obesity and osteoporosis share some common genetic determinations and the fact that the VDR is widely distributed, is controlling genes related to bone metabolism, chronic diseases, and inflammation. Consequently, it is fundamental to verify, characterize, and correlate the occurrence of such genetic variations of the VDRs. This will propose a personalized clinical approach to prohibit or at least postpone the development of these chronic diseases and subsequent complications. From this point of view, this study was conducted to evaluate the genetic association of selected polymorphic variants within the VDR gene, particularly Apal (rs7975232) and TaqI (rs731236), in obesity development and osteoporotic risk, among a sample of Egyptian females, a country where obesity is reaching endemic proportions.

**Methods**

This was a cross-sectional study, which included 97 Egyptian women. Their ages ranged between 25 and 65 years with a mean age of 48.85 ± 9.88 years. They were recruited and randomly chosen, from all employees and workers, of all categories, of the “National Research Centre”, Egypt. All participated women were free from any chronic disease or under long-term medications. A written informed consent was obtained from all participants after being informed about the purpose of the study. This research paper was derived from a cross-sectional survey of a project funded by “National Research Centre”, Egypt, 2016–2019 entitled “Bone mass among Overweight and Obese Women: Mechanism and Intervention.” “National Research Centre”, with an approval obtained from the Ethics Committee of “National Research Centre” (registration number is 16/127).

For each participant woman, anthropometric measurements, dual-energy X-ray absorptiometry (DEXA) measurements, and molecular genetic analysis were done.

**Anthropometric measurements**

Body weight and height were measured, following the recommendations of the “International Biological Program” [16]. Body weight (Wt) was determined to the nearest 0.01 kg using a Seca Scale Balance, with the woman wearing minimal clothes and with no shoes. Body height (Ht) was measured to the nearest 0.1 cm using a Holtain portable anthropometer. Body mass index (BMI) was calculated: [BMI: weight (in kilograms) divided by height (in meters squared)]. The participant women were classified according to their BMI into 2 groups: 31 women with normal BMI (<25 kg/m²) and 66 overweight/obese women (≥ 25 kg/m²).

**DEXA measurements**

Both bone mineral density “BMD” (gm/cm²) and BMD T score at the neck of the femur were measured using dual-energy DEXA (DEXA Norland XR-46 version 3.9.6/2.3.1, USA). A full body DEXA scan, based on the woman’s age, weight, and height, was performed with the participant keeping the precise distance between her arms and legs according to the machine instruction manual. A well-qualified operator executed and evaluated all analyses using the same protocol for all assessments. According to the WHO diagnostic criteria [17]
depending on BMD T score at any of the recommended sites (lumbar spine or femoral neck), the women were classified into 3 groups: women with healthy bone ( > −1), osteopenia (between −1 and > −2.5), and osteoporosis (< −2.5) [18]. After that, BMD T score −1 was taken to group the participating women to a non-osteoporotic or osteoporotic group.

Molecular genetic analysis
Genomic DNA extraction
Genomic DNA was extracted using Qiagen QIAamp DNA Blood Mini Kit from whole blood samples according to the manufacturer’s protocol. The concentration of genomic DNA was determined by quantitative method, based on optical density measurement using NanoDrop UV/V (Thermo Scientific, UK). The purity of DNA was determined by calculating the ratio of absorbance at 260 nm to absorbance at 280 nm ($A_{260}/A_{280}$). Pure DNA should have an $A_{260}/A_{280}$ ratio of 1.7–1.9, respectively.

VDR gene polymorphism genotyping by PCR-restriction fragment length polymorphism (RFLP)
The ApaI and TaqI polymorphic sites of VDR were considered. The targeted SNP was amplified by conventional polymerase chain reaction (PCR) and followed by restriction digestion. The VDR genotype of each subject was identified according to the digestion pattern and alleles.

TaqI polymorphism PCR amplification: PCR reaction was carried out in 25-μL reaction mixture containing 1.5 mM MgCl2, 0.2 mM dNTP, and 10 pmols of each primer sequences F: 5’-CAA CCA AGA CTA CAA GTA CCG CGT CAG TGA-3’ and R: 5’-CAC TTC GAG CAC AAG GGG CGT TAG C-3’ as described previously by Mohamed and El-Askary [19], 0.5 U of Taq DNA polymerase, and 200ng of genomic DNA. PCR conditioning was as follows: initial denaturation for 5 min at 95°C, 30 cycles of 30s at 95°C, 45s at 57°C, extension for 60s at 72°C, and a final extension for 5 min at 72 °C.

ApaI polymorphism PCR amplification: PCR reaction was carried out in 25-μL reaction mixture containing 1.5 mM MgCl2, 0.2 mM dNTP, and 10 pmols of each primer sequences F: 5’-CAA CCA AGA CTA CAA GTA CCG CGT CAG TGA-3’ and R: 5’-CAC TTC GAG CAC AAG GGG CGT TAG C-3’ as described previously by Mohamed and El-Askary [19], 0.5 U of Taq DNA polymerase, and 200ng of genomic DNA. PCR conditioning was as follows: initial denaturation for 5 min at 95°C, 30 cycles of 30s at 94°C, annealing for 45s at 57°C, extension for 60s at 72°C, and a final extension for 5 min at 72 °C.

Post-PCR-RFLP: The resulting DNA fragments were subjected to restriction digestion using respective enzymes ApaI and Taq-I (Promega, Madison, USA, 10 U/ml). The Eppendorf tubes for RFLP were prepared as follows: 10 μl of PCR product; 16.3 μl of sterile, deionized water; 0.2 μl of 100X BSA; and 2 μl of 10X RE Buffer, and mixed by pipetting. Finally, 10 units of each of the respective restriction enzymes were added. The tubes were incubated (2 h at 37°C for ApaI and Taq I polymorphisms) and heat inactivated for 15 min at 80°C. The genotypes were resolved on 2% (w/v) agarose gels.

3-Genotyping: The genotypes were resolved on 2% (w/v) agarose gels. ApaI polymorphism genotyping for wild type homozygosis fragment (AA) at 740-bp mutant homozygosis fragments (aa) at 530 and 210 bp and heterozygosis produces fragment (Aa) of 740, 530, and 210 bp. In the presence of A-allele, there was no restriction enzyme cleavage site and a product of 740 bp was obtained. In subjects carrying “a-allele,” the cleavage products of 530 and 210 bp were detected. Alleles “A” and “a” were assigned based on the presence of a 740-bp (uncleaved) fragment and the 530-bp and 210-bp (cleaved) fragments, respectively (Fig. 1). TaqI polymorphism genotyping for wild type homozygosis

![Fig. 1 The genotypes of VDR gene polymorphism using Apal restriction enzyme, 100-bp DNA marker (NEB). Lanes 1, 2, and 5: Apal with homozygote genotype; uncleaved Apal site fragment 740 bp. Lanes 3, 4, and 6: Apal with heterozygote genotype; heterozygosis fragments 740, 530, and 210 bp.](image-url)
produces fragment (TT) at 495 bp while heterozygosis produces fragments (Tt) at 495, 290, and 205 bp. The allele “T” was associated with the presence of a 495-bp fragment, while allele “C” was assigned in the presence of 290-bp and 205-bp fragments (Fig. 2).

Statistical analysis
Data were analyzed using the Statistical Package for Social Sciences (SPSS/Windows version 16, SPSS Inc., Chicago, IL, USA). The normality of data was tested using the Kolmogorov-Smirnov test. The data of DEXA, weight, and BMI were not normally distributed. So, non-parametric tests were used.

The 97 participant women were classified twice into 2 groups: first according to their BMI (31 normal weight and 66 overweight/obese) and second according to their BMD T score (23 osteoporotic and 74 non-osteoporotic). The parametric data were expressed as mean ± SD, where the qualitative ones were expressed as number and percentage (%). The various parametric variables of the different groups were analyzed and compared using the Mann-Whitney test for independent groups, while the frequency distribution of the vitamin D receptors among different groups (non-parametric data) were compared using the chi-square test. P < 0.05 was regarded as statistically significant for all tests.

Results
Frequency distribution of VDR gene polymorphisms (TaqI and ApaI) among non-osteoporotic and osteoporotic groups (Table 1) revealed that Apal polymorphism was significantly associated with BMD (P = 0.012). The homozygote Apal genotype was the most abundant among osteoporotic women (95.7%), while the heterozygote one was more frequent among non-osteoporotic women (35.1%). Meanwhile, the frequency distribution of VDR (Apal and TaqI) genes among overweight/obese cases and the normal weight group (Table 2) showed insignificant differences in the distribution of VDR polymorphisms.

Comparisons of the means ± SD of BMI and BMD at the femur neck between genotypes of Taq I and Apal VDR gene polymorphisms among different groups are presented in Tables 3 and 4. Among the normal weight women (Table 3), the Taq I genotype of VDR had a significant effect on BMD value and osteoporotic risk, as the heterozygote genotype of TaqI VDR gene polymorphism had higher BMD than the homozygote one in the same group (P = 0.000).

When groups were divided according to the presence or absence of osteoporosis (osteoporosis risk) (Table 4), BMI values differ by VDR gene polymorphisms in the case of TaqI and this difference was statistically significant (P = 0.032). BMI was increased among women carrying the homozygote genotype of Taq I VDR gene in the non-osteoporotic group, while increased BMI was associated with the heterozygote Taq I genotype in the osteoporotic group.

Discussion
The abundant distribution of VDRs in skeletal and nonskeletal tissues and its existence in several cellular

Table 1 Frequency distribution of TaqI and ApaI genotypes among non-osteoporotic and osteoporotic groups

| Variables | Non-osteoporotic (N = 74) | Osteoporotic (N = 23) | Chi-square |
|-----------|---------------------------|-----------------------|------------|
|           | N | % | N | % |               |
| Vit. D receptor | | | | | |
| TaqI     |   |   |   |   |               |
| Homo     | 42 | 56.8 | 18 | 78.3 | 0.064 |
| Hetero  | 32 | 43.2 | 5 | 21.7 |         |
| ApaI     |   |   |   |   |               |
| Homo     | 47 | 63.5 | 22 | 95.7 | 0.012* |
| Hetero  | 26 | 35.1 | 1 | 4.3 |         |
| Mutant  | 1 | 1.4 | 0 | 0 |         |

N.B. *P < 0.05 = significant differences
cascades indicates its crucial role in the pathophysiology of many diseases [20, 21]. Numerous studies investigated the association between VDR variants (ApaI and TaqI) and bone disorders and disparate results were detected. The current study found a significant association between ApaI VDR genotypes and osteoporosis in Egyptian women. This finding was supported and pooled in a large meta-analysis performed by Zhang et al. [22] who reported that there were significant correlations between VDR ApaI and postmenopausal osteoporosis susceptibility in the Caucasian populations and indicating that postmenopausal females having mutant allele of VDR ApaI might have less susceptibility to osteoporosis compared to those with wild genotype. Also, our results identified higher BMD among the normal weight women group carrying the heterozygote genotype of the VDR TaqI polymorphism than those with the homozygote one and this difference is statistically significant. In agreement with our results, in Belarusian osteoporotic postmenopausal women, both ApaI and TaqI genetic variations were found to be introducing factors of osteoporosis [23].

On contrary, a meta-analysis study by Shen et al. [24], of total 6500 osteoporotic women, showed that no association was found among the ApaI and TaqI polymorphisms and the prevalence of bone fracture. Also, Wang et al. [25] and Zhang et al. [22] conducted meta-analyses of 18 studies of VDR TaqI polymorphism and reported no significant relationship between TaqI polymorphism and osteoporosis incidence, while in Yadav et al. [26] meta-analysis, a total of 65 (14929 samples), 31 (7697 samples), 18 (3617 samples), and 26 (5353 samples) were studied. The authors found that the recessive model of TaqI polymorphism is associated with osteoporosis in the Caucasian population. The other polymorphism ApaI has no significant effect in low bone density. The prevalence of various VDR gene natural variants varies in numerous ethnic/regional populations. Due to this, the influence of these variations might vary from ethnic group to another. In addition, they provided that various gene to gene interactions and the epigenetic role of the environment should also be extensively studied in the future, as it could explain the genetics of osteoporosis [26]. Sakamoto et al. [27] study on 499 Japanese women showed that the VDR TaqI genotypes are significantly associated with bone mass in young Japanese women. Among them, the VDR ApaI heterozygote genotype is associated with increased bone mass concomitant with higher calcium intake.

In the current study, a significant association between TaqI VDR SNPs and obesity phenotype was found when

| Table 2 | Frequency distribution of TaqI and ApaI genotypes among overweight/obese and normal weight groups |
|----------|--------------------------------------------------|
| Variables | Overweight/obese (N = 66) | Normal weight (N = 31) | Chi-square |
|          | N | %  | N | %  |          |
| Vit. D receptor | | | | | |
| TaqI | | | | | |
| Homo | 43 | 65.2 | 17 | 54.8 | 0.330 |
| Hetero | 23 | 34.8 | 14 | 45.2 | |
| ApaI | | | | | |
| Homo | 44 | 66.7 | 25 | 80.6 | 0.329 |
| Hetero | 21 | 31.8 | 6 | 19.4 | |
| Mutant | 1 | 1.5 | 0 | 0 | |

| Table 3 | Comparisons of means ± SD of BMI and BMD between different genotypes of TaqI and ApaI VDR among overweight/obese and normal weight women |
|----------|--------------------------------------------------|
| Variables | TaqI | ApaI |
| Overweight/obese (N = 66) | HOMO (N = 43) | Hetero (N = 23) | P | HOMO (N = 44) | Hetero (N = 22) | P |
| Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD | |
| BMI | 34.44 ±5.46 | 36.56 ±9.13 | 0.652 | 35.19 ±6.96 | 35.56 ±7.05 | 0.888 |
| BMD T score at the femur neck | −1.40 ±1.16 | −1.41 ±1.45 | 0.928 | −1.38 ±1.36 | −1.41 ±1.03 | 0.968 |
| Normal weight women (N = 31) | HOMO (N = 17) | Hetero (N = 14) | P | HOMO (N = 25) | Hetero (N = 6) | P |
| Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD | |
| BMI | 22.46 ±1.74 | 22.68 ±1.99 | 0.597 | 22.29 ±1.95 | 23.66 ±0.15 | 0.105 |
| BMD T score at the femur neck | −2.90 ±0.47 | −1.96 ±0.25 | 0.000** | −2.53 ±0.66 | −2.23 ±0.17 | 0.314 |

N.B. BMI/ body mass index, BMD bone mineral density; *P < 0.01 = highly significant differences
studied groups were subdivided according to the presence of osteoporosis. Chen et al. [28] performed meta-analysis studies, including 1188 obese patients and 1657 healthy controls, to study the relationship between VDR polymorphisms and the incidence of obesity based on several case-control studies. Among them, the presence of the VDR Apal natural variant with obesity susceptibility was investigated in 3 studies [11, 29, 30] and the TaqI polymorphism by Yiannis et al. [31], Fan et al. [29], Al Hazmi et al. [11], and Bienertová-Vašků et al. [30]. This meta-study reported that the T allele of TaqI could have a preservative role it could not find in the relationship between Apal polymorphism and the incidence of obesity. Ruiz-Ojeda and his colleagues [32] hypothesized that allelic variations in the VDR gene might be potential targets for genetic therapy. One of the main limitations in our work is the lack of control of confounding factors such as smoking. Second is the small sample size enrolled in the current study of Egyptian females; so, future studies in larger scale should focus on multiple haplotypes, to clarify the possible overall impacts of common VDR polymorphisms.

### Limitations

One of the main limitations in our work is the lack of control of confounding factors such as smoking. Second is the small sample size enrolled in the current study of Egyptian females; so, future studies in larger scale should focus on multiple haplotypes, to clarify the possible overall impacts of common VDR polymorphisms.

### Conclusions

The heterozygote TaqI genotype seems to be protective against the osteoporosis phenotype and it was accompanied with increased BMI among osteoporotic women, while the homozygote Apal genotype has a significant association with osteoporosis risk. These polymorphisms may be considered useful markers for the screening of osteoporosis and obesity in certain ethnicities and may be potential targets for genetic therapy.

### Abbreviations

- BMI: Body mass index
- DEXA: Dual-energy X-ray absorptiometry
- DZ twins: Dizygotic twins
- MZ twins: Monozygotic twins
- PCR: Polymerase chain reaction
- RFLP: Restriction fragment length polymorphism
- RXR: Retinoic acid receptor
- VC: Waist circumference
- WHO: World Health Organization
- 1, 25(OH)2D: 1, 25-Dihydroxy-vitamin D
- BMD: Bone mineral density
- DEXA: Dual-energy X-ray absorptiometry
- DZ twins: Dizygotic twins
- Ht: Body height
- MS: Metabolic syndrome
- MZ twins: Monozygotic twins
- PCR: Polymerase chain reaction
- RFLP: Restriction fragment length polymorphism
- RXR: Retinoic acid receptor
- VC: Waist circumference
- Wt: Body weight
- WHO: World Health Organization

### Acknowledgements

We would like to acknowledge our institute ‘National Research Centre, Egypt’; without its fund, this study could not be done. The authors are also grateful to everybody who participated in this study, the employers of our institute who were the participants of this study, and the doctors who

### Table 4

| Variables | TaqI | ApaI |
|-----------|------|------|
|           | Non-osteoporotic women (N = 74) | Osteoporotic women (N = 23) |
|           | HOMO (N = 42) | Hetero (N = 32) | HOMO (N = 47) | Hetero (N = 26) |
|           | Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD |
| BMI       | 33.47 ±6.31 | 30.65 ±8.88 | 32.10 ±7.34 | 32.72 ±8.07 |
| BMD T score at the femur neck | −1.34 ±1.12 | −1.38 ±1.05 | 0.845 ±1.24 | −1.15 ±1.56 |

N.B. BMI: body mass index; BMD: bone mineral density; *p < 0.05 = significant differences.
participated in the collection of the data. Without their help, this study could not have been completed.

**Authors’ contributions**

NE is the principal investigator (P.I.) and designed the project and the study as well revised every step of the project and gave conceptual advice; SA is the co-PI of the project from which this data was derived, performed the statistical analysis, and shared in the tabulation of the data and publication process; WA wrote the draft of the manuscript; Gh.N and RM were responsible about the genetic analysis; A.Kh performed the DEXA scan and the anthropometry measurements; MM and MA had taken anthropology measurements. All authors read and have approved the submitted version. They have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

**Funding**

This research paper was derived from a project funded by the National Research Centre (NRC), Egypt, 2016–2019 entitled “Bone mass among Overweight and Obese Women: Mechanism and Intervention.” (11th Research Plan of the NRC), as part of our jobs.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request, after taking the permission of our institute “National Research Centre.”

**Declarations**

**Ethics approval and consent to participate**

A written informed consent was obtained from all participants after being informed about the purpose of the study. This research paper was derived from a cross-sectional survey of a project funded by the National Research Centre (NRC), Egypt, 2016–2019 entitled “Bone mass among Overweight and Obese Women: Mechanism and Intervention.” (11th Research Plan of the NRC), with an approval obtained from the Ethics Committee of NRC (registration number is 16/1/127).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Biological Anthropology Department, Medical Research Division, National Research Centre, 33 El-Bootho St, Dokki, Cairo, Giza 12622, Egypt.
2. Molecular Genetics and Enzymology Department, Human Genetics and Genome Division, National Research Centre, Cairo, Egypt.

Received: 24 March 2021 Accepted: 26 July 2021

**References**

1. Greco EA, Lenzi A, Migliaccio S (2015) The obesity of bone. Ther Adv Endocrinol Metab. 6(6):273–286.
2. Trevisan C, Alessi A, Girotti G, Zanferrini BM, Bertocco A, Mazzochin M, Zoccarato F, Piovesan F, Di Nian M, Giannini S, Manzato E, Sergi G (2020) The impact of smoking on bone metabolism, bone mineral density and vertebral fractures in postmenopausal women. J Clin Endocrinol Metab. 105(3):381–389.
3. El-Zanaty and Associates [Egypt], International (2015) Egypt demographic and health survey 2014: Ministry of Health and Population and ICF International, Cairo and Rockville.
4. Horowitz MC, Lorenzo JA (2004) The origin of osteoclasts. Curr Opin Rheumatol. 16:464–468.
5. Nakamura T (2004) WHO diagnostic criteria for osteoporosis and trends in Europe and USA. Nihon Rinsho 62(Suppl 2):235–239.
6. Lyon HN, Hirschhorn JN (2005) Genetics of common forms of obesity: a brief overview. Am J Clin Nutr 82(1):1255–2175. https://doi.org/10.1093/ajcn/82.1.2155.
7. Caftberg C (2019) Nutrigenomics of vitamin D. Nutrients 11(3):676. https://doi.org/10.3390/nu11030676.
8. Hewison M, Zehnder D, Chakraverty R, Adams JS (2004) Vitamin D and barrier function: a novel role for extra-renal 1α-hydroxylase. Mol Cell Endocrinol 215(1-2):31–38. https://doi.org/10.1016/j.mce.2003.11.017.
9. Utterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP (2004) Genetics and biology of vitamin D receptor polymorphisms. Gene. 338(2):143–156. https://doi.org/10.1016/j.gene.2004.05.014.
10. Banjari AA, Al-Ghafani AR, Koman N, Fallatah SM (2020) Genetic influence of vitamin D receptor gene polymorphisms on osteoporosis risk. Int J Health Sci (Qassim) 14(4):22–28.
11. AH-Zamini AS, Al-Mehmadi MM, Al-Bogami SM et al (2017) Vitamin D receptor gene polymorphisms as a risk factor for obesity in Saudi men. Electron Physician 10(10):5427–5433. https://doi.org/10.19082/5427.
12. Man H, Yu Z, Dan L et al (2018) Association between −174G>C polymorphism in the IL-6 promoter region and the risk of obesity: a meta-analysis. Medicine. 97:e11773.
13. Shab-Bidar S, Neyestani TR, Djazayery A (2017) Vitamin D receptor gene polymorphisms, metabolic syndrome, and type 2 diabetes in Iranian subjects: no association with observed SNPs. Int J Vitam Nutr Res 10:1–10.
14. Hasan HA, AbuOudeh RO, Mada WAMW, Mohamed HIB, Samudin AR (2017) Association of vitamin D receptor gene polymorphisms with metabolic syndrome and its components among adult Arabs from the United Arab Emirates. Diabetes Metab Syndr 11(Suppl 2):531–537.
15. Correa-Rodriguez M, Carrillo-Avila JA, Schmidt-RioValle J, Gonzalez-Jimenez E, Vargas S, Martin J et al (2018) Genetic association analysis of vitamin D receptor gene polymorphisms and obesity-related phenotypes. Gene. 640:51–56. https://doi.org/10.1016/j.gene.2017.10.029.
16. Hiemaux J, Tanner JM (1969) Growth and physical studies. In: Weiner JS, Lourie SA (eds) Biology human. A guide to field methods. IBP. London, Blackwell Scientific Publications; 1969, Oxford.
17. WHO Scientific Group on the Prevention and Management of Osteoporosis: Geneva, Switzerland (2003). Prevention and management of osteoporosis: report of a WHO scientific group. World Health Organization. Tech Rep Ser 2003;921:1–164. https://www.who.int/hdr/file/10665/42841.
18. NIH Consensus Statement (2000). Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17(1):1–45.
19. Mohamed S, El-Ashkary A (2017) Vitamin D receptor gene polymorphism among Egyptian obese children. Asian J Clin Nutr 9:24–29.
20. Pludowski P, Holick MF, Grant WB, Konstantynowicz J, Masurehens HR, Haq A (2018) Vitamin D supplementation guidelines. J Steroid Biochem Mol Biol 175:125–135. https://doi.org/10.1016/j.jsbmb.2017.01.021.
21. Sirajudeen S, Shah I, Al MA (2019) A narrative role of vitamin D and its receptor with current evidence on the gastric tissues. Int J Mol Sci 20(15):3832. https://doi.org/10.3390/ijms20153832.
22. Zhang L, Yin X, Wang J, Xu D, Wang Y, Yang J, Tao Y, Zhang X, Feng Y, Yan C (2018) Associations between VDR gene polymorphisms and osteoporosis risk and bone mineral density in postmenopausal women: a systematic review and meta-analysis. Sci Rep 17(1):581.
23. Marozi P, Mosse L, Alekna V, Rudenko E, Tamulaitienė M, Ramanau H et al (2013) Association between polymorphisms of VDR, COL1A1, and LCT genes and bone mineral density in Belarusian women with severe postmenopausal osteoporosis. Medicina (Kaunas) 49:177–184 [PubMed] [Google Scholar].
24. Shen H, Xie J, Lu H (2014) Vitamin D receptor gene and risk of fracture in postmenopausal women: a meta-analysis. Cimat. 17(4):319–324. https://doi.org/10.3390/ijms17043194.
25. Wang QX, Zhao SM, Zhou YB, Zhang C (2018) Lack of association between vitamin D receptor genes BsmI as well as Apal polymorphisms and osteoporosis risk: a pooled analysis on Chinese individuals. Int J Rheum Dis 21(5):967–974. https://doi.org/10.1111/1756-185X.13282.
26. Yadav U, Kumar P, Rai V (2020) Vitamin D receptor (VDR) gene FokI, BsmI, Apal and TaqI polymorphisms and osteoporosis risk: a meta-analysis. Egypt J Med Human Genet 21(1):15. https://doi.org/10.1186/s43042-020-00057-5.
27. Sakamoto Y, Oono F, Iida K, Wang PL, Tachi Y (2021) Relationship between vitamin D receptor gene polymorphisms (BsmI, TaqI, Apal, and FokI) and calcium intake on bone mass in young Japanese women. BMC Womens Health 21(1):76. https://doi.org/10.1186/s12905-021-01222-7.
28. Chen X, Wang W, Yanyan Wang Y, Han X, Gao L (2019) Vitamin D receptor polymorphisms associated with susceptibility to obesity: a meta-analysis. Med Sci Monit 25:8297–8305
29. Fan HR, Lin LQ, Hao MA et al (2015) Association between vitamin D receptor gene polymorphism (TaqI) and obesity in Chinese population. J Genet 94(3):473–478. https://doi.org/10.1007/s12041-015-0541-x
30. Bienertova-Vasku J, Zlamal F, Pohorala A, Mikes O, Goldbergova-Pavkova M, Novak J et al (2017) Allelic variants in vitamin D receptor gene are associated with adiposity measures in the central-European population. BMC Med Genet 18(1):90. https://doi.org/10.1186/s12881-017-0454-z
31. Yiannis V, Theologia S, Kalliopi K et al (2013) VDR TaqI is associated with obesity in the Greek population. Gene. 512:237–239
32. Ruiz-Ojeda FJ, Anguita-Ruiz A, Leis R, Aguilera OM (2018) Genetic factors and molecular mechanisms of vitamin D and obesity relationship. Ann Nutr Metab 73:99
33. Karonova T, Grineva E, Belyaeva O, Bystrova A, Jude EB, Andreeva A, Kostareva A, Pihudowski P (2018) Relationship between vitamin D status and vitamin D receptor gene polymorphisms with markers of metabolic syndrome among adults. Front Endocrinol (Lausanne) 9:948
34. Nam SW, Choi J, Jeon HJ, Oh TK, Lee DH (2021) The associations between vitamin D receptor BsmI and Apal polymorphisms and obesity in Korean patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 14:557–564

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.